Skip to main content
Equibles

Creative Planning

Position in EDIT — Editas Medicine, Inc.

CIK 1540235 OVERLAND PARK, KS
Back to EDIT Full portfolio

Position in EDIT

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$147,653
+$90,636 QoQ
Shares Held
45,572
+97.4% QoQ
Ownership
0.030%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#84
of 216 holders
Holding Since
Mar 2020
11 quarters on record
Voting authority Sole 0% Shared 0% None 100%

Common Shares in EDIT Over Time

Shares Held

Position Value (USD)

Derivatives in EDIT

reported options exposure · as of Dec 31, 2020
CallValue
$35,055
CallShares
500
PutValue
$0
PutShares
0

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

Creative Planning holds $457,365,908 across 219 Biotechnology names. EDIT ranks #181 (0.0% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 VRTX
Vertex Pharmaceuticals Inc / Ma
 127,672 $63,418,511
2 REGN
Regeneron Pharmaceuticals, Inc.
 36,949 $23,039,178
3 EXEL
Exelixis, Inc.
 270,292 $14,706,586
4 INCY
Incyte Corp
 110,664 $12,544,870
5 CYTK
Cytokinetics Inc
 141,939 $12,091,783
6 RVMD
Revolution Medicines, Inc.
 64,120 $12,008,393
7 ARGX
Argenx SE
 12,744 $11,823,500
8 BMRN
Biomarin Pharmaceutical Inc
 153,161 $8,763,872

All Filings in EDIT

Export CSV
13 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $147,653 45,572
2026-03-31 $57,017 23,084
2024-09-30 $73,529 21,563
2024-06-30 $47,120 10,090
2022-03-31 $4,755 250
2021-06-30 $211,607 3,736
2021-03-31 $715,470 17,035
2020-12-31 $799,324 11,401
2020-12-31 $35,055 500
2020-09-30 $2,000 500
2020-09-30 $431,254 15,369
2020-06-30 $455,443 15,397
2020-03-31 $754,868 38,067